We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
Read MoreHide Full Article
Ultragenyx Pharmaceutical (RARE - Free Report) announced that the European Commission (EC) has expanded the eligible patient population for one of its marketed products, Evkeeza (evinacumab), an ANGPTL3 inhibitor. Per the latest approval, Evkeeza is now indicated as an adjunct to diet and other lipid-lowering therapies to treat children aged six months and older with homozygous familial hypercholesterolemia (HoFH). The EC’s approval makes Evkeeza the first HoFH medicine indicated for this pediatric population in the EU.
HOFH is an inherited disease that causes dangerously high levels of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol. It affects approximately 1,600 people in the EU and 1 in 300,000 globally. Please note that Evkeeza was initially approved in the EU in 2021 as an adjunct to diet and other LDL-C-lowering therapies to treat adult and adolescent patients aged 12 years and older with HoFH. The drug’s label was later expanded in 2023 to include the treatment of children aged 5-11 years old with HoFH. The drug is also approved in multiple other geographies for the HoFH indication like the United States, United Kingdom and Canada, among others.
In the past three months, shares of Ultragenyx have plunged 20% compared with the industry’s 9.4% decline.
Image Source: Zacks Investment Research
More on Evkeeza’s Label Update for Younger HoFH Patients
Please note that the EC’s approval forEvkeeza to treat HoFH patients aged six months and older follows the positive recommendation received from its advisory committee in November 2024.
Evkeeza's efficacy in pediatric patients aged six months to less than five years with HoFH has been predicted through model-based extrapolation. These analyses suggest that this age group is expected to experience a similar or greater reduction in LDL-C at week 24 compared to adults when given a 15 mg/kg dose of the drug, every 4 weeks. Additionally, supportive data for five HoFH patients aged 1 to 4 years who receive Evkeeza via compassionate use also showed a clinically meaningful LDL-C reduction consistent with 5 years or older pediatric patients in clinical studies. The safety profile for this younger age group is expected to align with that of older pediatric patients, with no new safety concerns identified.
Please note that Evkeeza was originally discovered and developed by Regeneron Pharmaceuticals (REGN - Free Report) . In 2022, Ultragenyx signed a licensing agreement with Regeneron for Evkeeza to treat HoFH. Per the deal, RARE obtained the rights to develop, commercialize and distribute Evkeeza outside the United States. The regions include the European Economic Area. The collaboration with Regeneron for Evkeeza gives Ultragenyx a fourth-approved product that adds to the top line. However, REGN solely commercializes Evkeeza in the United States.
RARE’s Other Marketed Products
Ultragenyx’s commercial portfolio comprises three other medicines — Mepsevii (vestronidase alfa), Crysvita (burosumab) and Dojolvi (UX007).
Mepsevii is approved for the treatment of children and adults with Mucopolysaccharidosis VII, also known as Sly syndrome.
Crysvita, an antibody targeting fibroblast growth factor 23, is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. Crysvita received European conditional marketing authorization in February 2018 for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, and adolescents with growing skeletons. Crysvita has also been approved for another indication, tumor-induced osteomalacia, in adults and pediatric patients aged two years and older by the FDA in June 2020.
Dojolvi was approved by the FDA in 2020 for the treatment of pediatric and adult patients for all forms of long-chain fatty acid oxidation disorders with a molecularly confirmed diagnosis. Dojolvi is the first FDA-approved therapy for these lifelong and life-threatening genetic disorders and is now available to patients in the United States.
Ultragenyx Pharmaceutical Inc. Price and Consensus
In the past 30 days, 2024 estimates for Castle Biosciences’ earnings per share have remained constant at 34 cents. During the same timeframe, loss per share estimates for 2025 have remained constant at $1.84. In three months, shares of Castle Biosciences have lost 2.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 30 days, estimates for Vanda Pharmaceuticals’ 2024 loss per share have remained constant at 32 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In three months, Vanda’s shares have gained 6.7%.
VNDA has delivered a negative earnings surprise of 45.79% in the past four quarters.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
Ultragenyx Pharmaceutical (RARE - Free Report) announced that the European Commission (EC) has expanded the eligible patient population for one of its marketed products, Evkeeza (evinacumab), an ANGPTL3 inhibitor. Per the latest approval, Evkeeza is now indicated as an adjunct to diet and other lipid-lowering therapies to treat children aged six months and older with homozygous familial hypercholesterolemia (HoFH). The EC’s approval makes Evkeeza the first HoFH medicine indicated for this pediatric population in the EU.
HOFH is an inherited disease that causes dangerously high levels of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol. It affects approximately 1,600 people in the EU and 1 in 300,000 globally. Please note that Evkeeza was initially approved in the EU in 2021 as an adjunct to diet and other LDL-C-lowering therapies to treat adult and adolescent patients aged 12 years and older with HoFH. The drug’s label was later expanded in 2023 to include the treatment of children aged 5-11 years old with HoFH. The drug is also approved in multiple other geographies for the HoFH indication like the United States, United Kingdom and Canada, among others.
In the past three months, shares of Ultragenyx have plunged 20% compared with the industry’s 9.4% decline.
Image Source: Zacks Investment Research
More on Evkeeza’s Label Update for Younger HoFH Patients
Please note that the EC’s approval forEvkeeza to treat HoFH patients aged six months and older follows the positive recommendation received from its advisory committee in November 2024.
Evkeeza's efficacy in pediatric patients aged six months to less than five years with HoFH has been predicted through model-based extrapolation. These analyses suggest that this age group is expected to experience a similar or greater reduction in LDL-C at week 24 compared to adults when given a 15 mg/kg dose of the drug, every 4 weeks. Additionally, supportive data for five HoFH patients aged 1 to 4 years who receive Evkeeza via compassionate use also showed a clinically meaningful LDL-C reduction consistent with 5 years or older pediatric patients in clinical studies. The safety profile for this younger age group is expected to align with that of older pediatric patients, with no new safety concerns identified.
Please note that Evkeeza was originally discovered and developed by Regeneron Pharmaceuticals (REGN - Free Report) . In 2022, Ultragenyx signed a licensing agreement with Regeneron for Evkeeza to treat HoFH. Per the deal, RARE obtained the rights to develop, commercialize and distribute Evkeeza outside the United States. The regions include the European Economic Area. The collaboration with Regeneron for Evkeeza gives Ultragenyx a fourth-approved product that adds to the top line. However, REGN solely commercializes Evkeeza in the United States.
RARE’s Other Marketed Products
Ultragenyx’s commercial portfolio comprises three other medicines — Mepsevii (vestronidase alfa), Crysvita (burosumab) and Dojolvi (UX007).
Mepsevii is approved for the treatment of children and adults with Mucopolysaccharidosis VII, also known as Sly syndrome.
Crysvita, an antibody targeting fibroblast growth factor 23, is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. Crysvita received European conditional marketing authorization in February 2018 for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, and adolescents with growing skeletons. Crysvita has also been approved for another indication, tumor-induced osteomalacia, in adults and pediatric patients aged two years and older by the FDA in June 2020.
Dojolvi was approved by the FDA in 2020 for the treatment of pediatric and adult patients for all forms of long-chain fatty acid oxidation disorders with a molecularly confirmed diagnosis. Dojolvi is the first FDA-approved therapy for these lifelong and life-threatening genetic disorders and is now available to patients in the United States.
Ultragenyx Pharmaceutical Inc. Price and Consensus
Ultragenyx Pharmaceutical Inc. price-consensus-chart | Ultragenyx Pharmaceutical Inc. Quote
RARE’s Zacks Rank & Stocks to Consider
Ultragenyx currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) and Vanda Pharmaceuticals (VNDA - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, 2024 estimates for Castle Biosciences’ earnings per share have remained constant at 34 cents. During the same timeframe, loss per share estimates for 2025 have remained constant at $1.84. In three months, shares of Castle Biosciences have lost 2.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 30 days, estimates for Vanda Pharmaceuticals’ 2024 loss per share have remained constant at 32 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In three months, Vanda’s shares have gained 6.7%.
VNDA has delivered a negative earnings surprise of 45.79% in the past four quarters.